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Abstract
Objective: Herpes simplex virus type 1 (HSV-l)-derived vectors are known to be effective tools to deliver 
transgenes into normal and neoplastic anterior pituitary (AP) cells in vitro. Our objective was to assess 
the in vitro and in vivo effects of tsK/p-gal, a temperature-sensitive HSV-l-derived vector harbouring 
the E. coli p-galactosidase gene, on AP hormone secretion as well as on transgene expression in rat 
AP tumours (hyperplastic prolactinomas).
Design: The impact of vector infection on prolactin (PRL) and GH release was determined in vitro in 
normal and hyperplastic (Iactotrophic) dispersed AP cells exposed for 24 h to tsK/p-gal as well as in 
vivo in ectopic AP grafts. In some oestrogen-induced prolactinoma-carrying rats, vector suspension 
was stereotaxically injected into the glands to assess transgene expression in vivo.
Methods: GH and PRL release was measured by specific RIAs. In vivo transgene expression was 
assessed by immunohistochemistry for p-galactosidase and enzymohistochemistry (5-bromo-4- 
chIoro-3-indoIyI-p-D-gaIactopyranoside). Ectopic pituitary grafts and stereotaxic surgery were 
performed following standard procedures.
Results: At a multiplicity of infection of 0.5, the vector induced a 30 and 22% fall in PRL and GH 
release respectively in normal AP cells, whereas the corresponding hormone release inhibition for 
hyperplastic AP cells was 41 and 33% for PRL and GH respectively. In ectopic pituitary grafts, the 
effect of vector infection on hormone secretion was assessed by measuring serum PRL levels in the 
host rats every 5 days for 4 weeks post-grafting. In the pituitary-grafted rats that received the viral 
vector, serum PRL failed to increase to the levels achieved in control-grafted animals. Finally, pituitary 
tumours stereotaxically injected with tsI</[3-gaI showed widespread expression of the [3-gaIactosidase 
transgene around the injection areas.
Conclusions: The results reported here have implications for basic studies using gene transfer to 
pituitary gland as well as potential gene therapy approaches to pituitary diseases.
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Introduction
Gene transfer methodologies have become powerful 
tools for basic research studies and for therapeutic 
purposes. In recent years, we and others have provided 
evidence suggesting that viral vectors constitute 
suitable tools for the delivery of genes to neuroendo­
crine cells (1). Adenoviral and herpetic vectors were 
successfully used to transfer different genes into normal 
and neoplastic anterior pituitary (AP) cells in culture 
(2-8). Moreover, adenoviral vectors have been used to 
transfer in vivo the herpes simplex virus type 1 (HSV-1)- 
thymidine kinase (TIC) suicide gene to somatomammo- 
trophic tumour cells (GH3) grafted into nude mice as 
well as to oestrogen-induced rat Iactotrophic tumours 
(6-8).
HSV-l-derived vectors have been used less frequently 
than adenoviral vectors for gene transfer to the 
neuroendocrine system. The only herpetic vectors so 
far used in this system are those derived from tsK, a 
temperature-sensitive mutant of HSV-1. The genome of 
tsK vectors has a mutation in the ICP4 gene, the major 
transcriptional activator of HSV-1, which yields an 
inactive ICP4 product at or above 37 °C, thus 
precluding replication at these temperatures. As 
protein ICP4 is fully active at 31 °C, tsK mutants 
are replication competent at this permissive tempera­
ture (9, 10). Using the tsK/|3-gal vector, it has been 
previously shown that this kind of vector is capable of 
transducing pituitary-derived cell lines (AtT20 and 
GH3) as well as normal AP cells in vitro (3). Recently, 
another tsK-derived vector, tsK/CRH10, expressing the 
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rat corticotrophin-releasing hormone precursor (pre- 
proCRH (ppCRH)) was constructed. It was demonstrated 
that neural and glial, but not epithelial, cell lines 
infected with tsK/CRHIO correctly post-translationally 
process ppCRH and secrete biologically active CRH 
(11).
In order to assess the suitability of tsK vectors for 
functional studies and therapeutic approaches in the 
pituitary gland, we studied the effects of a tsK vector 
carrying the E. coli f>-galactosidase gene, on prolactin 
(PRL) and growth hormone (GH) secretion in normal 
and hyperplastic rat AP cells in vitro and in oestrogen- 
induced AP rat prolactinomas in vivo.
Materials and methods
HSV-1-derived recombinant viral vector
The virus used in these studies, tsK/(3-gal, was kindly 
provided by Dr Christopher M Preston, MRC Virology 
Unit, University of Glasgow, UK. This temperature­
sensitive mutant of HSV-1 (strain 17) contains the E. 
coli lacZ open reading frame cloned into the TK locus 
under the control of the HSV immediate-early 3 (IE3) 
gene promoter (Fig. 1). The vector was propagated by 
infecting baby hamster kidney (BHK21) cells growing 
at 31 °C. Cells were grown in minimum essential 
medium (Gibco, Buenos Aires, Argentina) supplemen­
ted with 10% foetal calf serum (Bioser, Buenos 
Aires, Argentina), L-glutamine (0.3 g/1), and non- 
essential amino acids (Sigma Chemical Co., St Louis, 
MO, USA). Cells were harvested when a cytopathic 
effect was evident and the virus purified and titrated 
according to standard procedures (10). Virus titre was 
5.OX1O8 plaque forming units (pfu)/ml. In order to 
assay for the presence of wild-type revertants, serial 
dilutions of supernatants from tsK/|3-gal-infected 
BHK21 cells grown at 37 °C were added to BHK21 
cells, which were subsequently grown at 31 °C for 7 
days. The ratio of wild-type revertants calculated from 
this test was found to be lower than 1:10s pfu.
I |TK lacZ IE3 TK
TR------------ ; TK --------
UL
Animals and prolactinoma induction
Adult (5- to 7-month-old) Sprague-Dawley rats, raised 
in our colony at INIBIOLP, were kept under a 12 h 
light: 12 h darkness cycle with water and food freely 
available. All experiments on animals were done in 
conformity with the Guidelines on the Handling and 
Training of Laboratory Animals published by the 
Universities Federation for Animal Welfare (12). 
Hyperplastic APs, also referred to here as pituitary 
tumours, were induced in adult females by weekly i.m. 
injections of 40 pig 17|3-oestradiol valerate (Sigma) in 
0.2 ml sunflower oil, carried out for 8 weeks.
In vitro experiments
In each experiment, an average of eight APs were cut 
with a razor blade into eight to ten pieces each, and 
placed in a Petri dish where they were washed twice 
with secretion medium (SM: Earle's balanced salt 
solution containing 1 g/1 glucose, 1 g/1 NaHCC>3, 
0.5% BSA and 30 mg/ml ascorbic acid, pH 7.4 
(Sigma)). The pieces were transferred to a plastic tube 
with 10 ml SM containing 32 mg collagenase type IV 
and 4 mg DNAse type I 4 (Sigma). After 1 h incubation 
at 37 °C under constant shaking, the resulting cell 
suspension was gently dispersed by pipetting, in order 
to eliminate cell clusters, and finally centrifuged at 
500 g for 10 min. The supernatant was discarded and 
cells were resuspended in culture medium (SM plus 
10% horse serum). Cell viability, evaluated by the 
Trypan blue exclusion test, was consistently higher 
than 90%. Cells were finally seeded in plastic tubes at a 
concentration of 5 X 10 s cells/ml and infected with 
tsK/|3-gal at the indicated multiplicity of infection 
(MOI). After 24 h incubation at 37 °C, tubes were 
centrifuged, the corresponding pellets resuspended in 
1 ml SM and incubated for 1 h at 3 7 °C. Tubes were 
centrifuged again and the supernatants collected and 
stored at —20 °C for hormone determinations.
In vivo experiments
Recipient female rats were placed under ketamine 
hydrochloride anaesthesia (40 mg/kg, i.p.) and their 
left kidney surgically exposed by a back incision. Then, 
an AP, freshly removed from a highly inbred female 
donor, was injected ex vivo with 1 jjiI of either saline 
(controls) or viral suspension containing 5 X 10s pfu 
tsK/(3-gal, and immediately placed under the kidney
Figure 1 Structure of the tsK/(3-gal genome, 
which is composed of unique long (UL) and 
unique short (Us) regions, flanked by inverted 
repeats (TRL, IR|_, IRs and TRS). The 
[3-galactosidase gene is inserted into the TK 
locus under the control of an IE3 promoter. The 
arrow indicates the direction of transcription. 
From (15), with some modifications. 
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capsule of the recipient. The kidney was then replaced 
within the abdominal cavity, muscle and skin were 
sutured and the animals were allowed to recover from 
anaesthesia in individual cages. Usually, rats recovered 
fully from surgery within a few hours.
In the grafted animals, blood samples were taken 
under light ether anaesthesia from the tail veins every 
5 days beginning on the day of surgery. Serum was 
separated and kept at —20 °C until hormone assays.
Some rats bearing oestrogen-induced prolactinomas 
received in each AP lobe a 1 jul intrapituitary injection 
containing 5 X 105 pfu isK/(3-gal. For this purpose, rats 
were anaesthetised with an i.m. injection of ketamine 
hydrochloride (40 mg/kg) plus xylazine (8 mg/kg) and 
placed into a stereotaxic frame. To access the AP lobes, 
the tip of a 26 gauge needle fitted to a 10 pl syringe 
was stereotaxically brought to the following coordi­
nates relative to the bregma: 5.6 mm posterior, 
10.4 mm ventral and 1 mm right and left, for each 
AP lobe (13). At the appropriate times, animals 
were killed for immunohistochemical assessment of 
transgene expression in the AP.
Hormone assays
Rat PRL and GH were assayed by specific RIAs using 
materials provided by Dr A F Parlow, Pituitary 
Hormones and Antisera Center, Harbor-UCLA Medical 
Center, Torrance, CA, USA. Values for PRL and GH are 
expressed in terms of the US National Hormone 




For pituitary immunohistochemistry, glands stereo­
taxically injected with tsK/|3-gal were fixed in Bourn's 
fluid and embedded in paraffin. Serial 4 |xm sections 
were obtained at different levels of the blocks following 
a ventral to dorsal sequence. Sections were incubated 
overnight at 4 °C with a 1/800 dilution of a rabbit anti- 
|3-galactosidase serum generated by us or with rabbit 
antiserum against rPRL (code: PRL-9), obtained from 
Dr A F Parlow, used at 1/100 dilution. After washing, 
sections were processed with the Vectastain ABC kit 
(Vector Laboratories, Burlingame, CA, USA), using 
diaminobenzidine as chromogen (Sigma).
In some experiments, stereotaxically injected pitu­
itary tumours were submitted to enzymohistochemistry 
for |3-galactosidase activity. Injected animals were killed 
2 days after surgery, and tumours fixed for 1 h in 4% 
paraformaldehyde-PBS at pH 7.2. Glands were incu­
bated overnight in 0.01% 5-bromo-4-chloro-3-indolyl- 
|3-D-galactopyranoside (X-gal; Calbiochem, San Diego 
CA, USA) solution and further fixed for 3 h. Specimens 
were then embedded in paraffin and processed for 
histology as indicated above.
Statistics
The level of significance of differences between 
released hormone concentrations in the in vitro 
experiments was assessed by one-way ANOVA. When 
appropriate, ANOVAs were followed by the Tukey's 
multiple range test to assess the significance of 
differences between means. A P value lower than 
0.05 was considered significant in all cases. The in 
vivo data were analysed by a split-plot design using 
the general linear model procedure employing the 
SAS software package (version 6.12; SAS Institute, 
Madison, WI, USA).
Figure 2 Macroscopic view of oestrogen-induced rat prolactinomas 
stereotaxically injected (1 pl, bilaterally) with either saline (upper 
panel) or tsK/(3-gal (lower panel). Two days after injection, glands 
were removed, fixed for 1 h and submitted to X-gal 
enzymohistochemistry. After blue colour development, glands were 
further fixed overnight. Glands are shown from the ventral side. 
Arrows indicate injection sites. For further details, see the text. 
Scale bar on the lower right corresponds to 0.5 mm.
www.eje.org
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Figure 3 Oestrogen-induced rat pituitary prolactinoma infected with fsK/p-gal and immunostained for [3-galactosldase. The vector was 
stereotaxically injected in 1 pl viral suspension (5 x 105 pfu) per lobe in the pituitary gland, and 3 days later transgene expression was 
assessed immunohistochemically. Immunostained cells show morphological features compatible with different endocrine cell 
populations (objective x16). Inset is a view of the same section at a higher magnification (objective x40).
Results
Pituitary transgene expression in vivo
In previous studies, it was shown that tsK/f>-gal 
efficiently transduced all endocrine AP cells in vitro, 
including lactotrophic and somatotrophic cells (3). 
Here, we expanded these studies by assessing transgene 
expression in the adenohypophysis in vivo. As expected, 
oestrogen-induced pituitary adenomas showed a high 
lactotrophic cell hyperplasia and generated a marked 
hyperprolactinaemia as well as a moderate hyper- 
somatotrophinaemia (data not shown). Pituitary adeno­
mas stereotaxically injected with tsK/|3-gal showed an 
intense expression of the |3-galactosidase transgene 
around the injection areas (Fig. 2). The infected areas 
probably correspond to the diffusion areas of viral 
suspension. Immunohistochemical analysis of these 
areas revealed a high level of transduction in vivo 
(Fig. 3).
www.eje.org
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Figure 4 Secretion of PRL (A) and GH (B) by AP cells from normal 
(•) and oestrogen-treated (O) rats infected with fsK/p-gal at 
increasing MOI values. Results are means±s.E.M. *P < 0.05 
differences from controls (MOI = 0) for each cell culture type. Also 
notice that left (normal cells) and right (hyperplastic cells) scales on 
y-axes are different; n = 4 for all groups. The figure shows one 
representative experiment from a total of six.
Impact of vector infection on GH and PRL 
secretion in vitro
Normal and hyperplastic AP cells exposed to tsK/f>-gal 
showed a significant reduction in both PRL and GH 
release (Fig. 4). At an MOI of 0.5 pfu/cell, the vector 
induced a 30 and 22% fall in PRL and GH release 
respectively in normal AP cells, whereas the corre­
sponding hormone release inhibition for hyperplastic 
AP cells was 41 and 3 3% for PRL and GH respectively. 
Thus, hyperplastic cells appeared to be more susceptible 
than normal AP cells to the inhibitory action of tsK/ 
[3-gal. The inhibitory action of the vector on normal 
cells was maximal at an MOI of 2 and 1 pfu/cell for 
PRL and GH release respectively, whereas in hyper­
plastic cells maximal inhibition was achieved at
Figure 5 Serum PRL levels In rats carrying a pituitary graft under 
the kidney capsule. One group was injected with fsK/p-gal (O) 
and the other with vehicle (•). Results are expressed as 
means±s.E.M., n = 10 for both groups.
MOI =0.5 pfu/cell for PRL release and MOI = 1 pfu/ 
cell for GH. In general, MOI values greater than 1 pfu/ 
cell did not bring about further reductions in hormone 
release.
Effect of tsK/fi-gal infection of pituitary 
grafts on host serum PRL
Initial trials showed that stereotaxic injections into the 
pituitary sometimes caused significant haemorrhages, 
which most likely were due to mechanical damage to 
the abundant vessels that surround this gland. Since 
these haemorrhages plus eventual mechanical damage 
to hypothalamic structures could randomly affect 
pituitary hormone secretion in both virus- and saline- 
injected animals, we chose to study the functional 
impact of vector infection in ectopic AP grafts. The ex 
vivo vector delivery approach used in this study 
permitted a better control of random artefacts, thus 
leading to more reproducible results.
Pituitaries grafted under the kidney capsule survived 
satisfactorily in most cases, showing a significant 
revascularisation and no signs of host-versus-graft 
rejection for at least 5 weeks (maximal length of time 
of our studies). This apparently substantial degree of 
histocompatibility is likely to arise from the high 
inbreeding of our animals. As expected, immunohisto­
chemical assessment of the grafts at different times 
post-surgery revealed a progressive hyperplasia of the 
lacto trophic cell population (data not shown) which 
was paralleled by a progressive hyperprolactinaemia 
that reached its maximum around the third week post­
grafting, beginning to decline gradually afterwards 
(Fig. 5). In the grafted rats that received the viral 
vector, serum PRL failed to increase to the levels 
achieved in the control-grafted animals (Fig. 4).
www.eje.org
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Discussion
HSV-1 is an enveloped double-stranded DNA virus with 
a genome of approximately 150 kb, encoding at least 
80 genes (14). This virus is able to infect cells lytically 
or establish latency, especially in some neurons. HSV-1- 
derived vectors have several advantages for gene 
therapy, which include the availability of several 
replication-defective mutants and the ability of the 
virus to establish latency in some neurons, as well as its 
large capacity for harbouring transgenes (up to 30 kb). 
Although HSV-l-derived vectors have been extensively 
used for gene transfer in the central nervous system 
(15), it is only in the last few years that they have been 
shown to possess the capability to transduce endocrine 
cells. Thus, it was reported that apoptosis could be 
prevented in pancreatic (3-cells by transducing them 
with an HSV-1 amplicon vector carrying the bcl-2 
gene, a result that points to the potential of this vector 
for the prevention of type 1 diabetes mellitus (16, 17). 
As indicated above, tsK vectors have been also shown to 
transduce normal and neoplastic AP cells efficiently in 
vitro (3). Our results reveal that infection of AP cells 
with an HSV-l-derived vector induces a decrease in 
PRL and GH secretion in vitro and PRL in vivo. In 
addition, in vitro studies with tsK/|3-gal showed that 
this vector inhibits the regulated secretion of adreno­
corticotrophic hormone in cultured rat AP cells (18), 
which is in line with the results reported here. The 
mechanisms involved remain unclear, but two proper­
ties of HSV-1 may explain our results. First, this type of 
vector is known to be highly cytotoxic in other cell 
types, although this effect appears at higher MOI values 
and longer post-infection times than in the experiments 
reported here (9). On the other hand, the HSV-1 virion 
host shutoff protein encoded by the UL41 gene reduces 
non-specifically cell mRNA half-life (19, 20). Further­
more, it has been demonstrated that the infection with 
tsK-derived vectors inhibits protein synthesis in pri­
mary cultures of neurons and glia (9). If these 
mechanisms are involved in the inhibitory action of 
tsK vector on AP hormone secretion remains to be 
determined. The possibility that a diffusible hormone 
release-inhibiting factor(s) is produced by the trans­
duced cells should also be considered. In any case, the 
present study extends the initial work in AP cell 
cultures by demonstrating that tsK vectors can also 
deliver their transgenes to experimental pituitary 
tumours in vivo and achieve a substantial level of 
expression in the target cells.
If future studies confirm that HSV-l-derived vectors 
are also effective at delivering therapeutic genes into 
primary pituitary tumours, herpetic vectors could 
become one of the systems of choice for gene therapy 
approaches to pituitary neoplasms (21). Overall, the 
present results have implications for basic studies and 
potential gene therapy approaches to pituitary 
diseases.
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